BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
PRINCETON, N.J., April 15, 2016 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products announced today that Dr. Elizabeth Garner, Chief Medical Officer will present on the topic of subject recruitment for the SECURE Phase 3 Study at Women’s Health 2016: The 24th Annual Congress in Washington, DC on April 17, 2016.
The poster presentation, titled “Social Media and Text Messaging Outreach in the Recruitment of Millennials into a Phase 3 Contraceptive Patch Study” will discuss the impact of the use of social media to recruit young women to participate in the SECURE Study, a Phase 3 trial of the investigational contraceptive patch, Twirla®.
The SECURE Study is a multicenter, single-arm, open-label Phase 3 clinical trial in which healthy women eighteen and over will receive treatment with the investigational patch for up to one year. The clinical trial will assess the effectiveness of the patch in preventing pregnancy using the Pearl Index as the primary contraceptive efficacy measure. Safety and tolerability will also be evaluated. Twirla contains the active ingredients ethinyl estradiol and levonorgestrel, both of which have an established history of efficacy and safety in currently marketed low-dose combination oral contraceptives. The patch is applied once weekly for three weeks followed by a patch-free week, and is designed to promote user compliance.
For more information, please visit http://www.academyofwomenshealth.org.
About Agile
Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate Twirla® (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com.
Contact: Mary Coleman 609-683-1880
